Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients

Autor: Goldinger, SM, Dummer, R, Baumgaertner, P, Mihic-Probst, D, Schwarz, K, Hammann-Haenni, A, Willers, J, Geldhof, C, Prior, JO, Kündig, TM, Michielin, O, Bachmann, MF, Speiser, DE

Publikováno v: European Journal of Immunology, vol. 42, no. 11, pp. 3049-3061
European Journal of Immunology

Optimal vaccine strategies must be identified for improving T-cell vaccination against infectious and malignant diseases. MelQbG10 is a virus-like nano-particle loaded with A-type CpG-oligonucleotides (CpG-ODN) and coupled to peptide(16-35) derived f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c2a961a5f3826a77e299439bc147982f
https://serval.unil.ch/notice/serval:BIB_FA34B494C8D3

Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis.

Autor: Pham JP; Department of Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, New South Wales, Australia., Rodrigues A; Department of Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, New South Wales, Australia., Goldinger SM; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Sim HW; Department of Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia., Liu J; Department of Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Publikováno v: Experimental dermatology [Exp Dermatol] 2024 Jan; Vol. 33 (1), pp. e14978. Date of Electronic Publication: 2023 Nov 16.

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.

Autor: Goldinger SM; University of Zurich, Department of Dermatology, Gloriastrasse 31 Zurich, 8091, Switzerland; Melanoma Institute Australia, The University of Sydney, The Poche Centre, 40 Rocklands Road North Sydney NSW 2060, Australia. Electronic address: Simone.goldinger@usz.ch., Buder-Bakhaya K; University Hospital Heidelberg, Department of Dermatology and National Center for Cancer (NCT), Im Neuenheimer Feld 460 Heidelberg, 69120, Germany. Electronic address: dr.buder@gmx.de., Lo SN; Melanoma Institute Australia, The University of Sydney, The Poche Centre, 40 Rocklands Road North Sydney NSW 2060, Australia. Electronic address: Serigne.Lo@melanoma.org.au., Forschner A; University of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany. Electronic address: andrea.forschner@med.uni-tuebingen.de., McKean M; University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA. Electronic address: Meredith.McKean@SarahCannon.com., Zimmer L; University Hospital Essen, Department of Dermatology, Essen & German Cancer Consortium, Partner Site Essen, Germany. Electronic address: lisa.zimmer@uk-essen.de., Khoo C; Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: chloe.khoo@petermac.org., Dummer R; University of Zurich, Department of Dermatology, Gloriastrasse 31 Zurich, 8091, Switzerland. Electronic address: Reinhard.dummer@usz.ch., Eroglu Z; Moffitt Cancer Center, Department of Cutaneous Oncology, 12902 Magnolia Drive, Tampa, FL 33612, USA. Electronic address: Zeynep.Eroglu@moffitt.org., Buchbinder EI; Dana Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. Electronic address: Elizabeth_buchbinder@dfci.harvard.edu., Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Napoli, Italy. Electronic address: paolo.ascierto@gmail.com., Gutzmer R; Skin Cancer Center, Department of Dermatology, Mühlenkreiskliniken, Ruhr University Bochum Campus Minden, Germany. Electronic address: Ralf.Gutzmer@ruhr-uni-bochum.de., Rozeman EA; Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Department of Medical Oncology and Immunology, Plesmanlaan 121 Amsterdam, 1066 CX, the Netherlands. Electronic address: l.rozeman@nki.nl., Hoeller C; Medical University of Vienna, Department of Dermatology, Waehringer Guertel 18-20, Vienna, 1090, Austria. Electronic address: christoph.hoeller@meduniwien.ac.at., Johnson DB; Vanderbilt University Medical Center, Department of Medicine, Nashville, TN, USA. Electronic address: douglas.b.johnson@vumc.org., Gesierich A; University Hospital Wuerzburg, Department of Dermatology, Wuerzburg, Germany. Electronic address: gesierich_a@ukw.de., Kölblinger P; Department of Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria. Electronic address: p.koelblinger@salk.at., Bennannoune N; Gustave Roussy and Paris-Saclay University, 114 rue Edouard Vaillant Villejuif Cedex, 94805, France. Electronic address: Naima.Beannoune@gustaveroussy.fr., Cohen JV; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: Justine.Cohen@pennmedicine.upenn.edu., Kähler KC; Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Arnold-Heller-Strasse 3, Haus C, Kiel, 24105, Germany. Electronic address: kckaehler@yahoo.de., Wilson MA; Perlmutter Cancer Center, NYU Langone Health, NYU School of Medicine, 160 E. 34th Street, New York, NY 10016, USA. Electronic address: Melissa.wilson@nyumc.org., Cebon J; Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, La Trobe University, 145 Studley Road, Heidelberg VIC, Melbourne, 3084, Australia. Electronic address: jonathan.cebon@onjcri.org.au., Atkinson V; University of QLD, Princess Alexandra Hospital, Greenslopes Private Hospital, 199 Ipswich Rd, Woolloongabba QLD 4102, Australia. Electronic address: Victoria.Atkinson@health.qld.gov.au., Smith JL; Crown Princess Mary Cancer Centre Westmead, Sydney, NSW, Australia. Electronic address: JessicaLouise.Smith@health.nsw.gov.au., Michielin O; Lausanne University Hospital, Department of Oncology, Precision Oncology Center, Rue du Bugnon 21, Lausanne, 1011, Switzerland. Electronic address: olivier.michielin@chuv.ch., Long GV; Melanoma Institute Australia, The University of Sydney, The Poche Centre, 40 Rocklands Road North Sydney NSW 2060, Australia; Royal North Shore Hospital, Reserve Road St Leonards NSW 2065, Australia; Mater Hospital, 25 Rocklands Road, North Sydney NSW 2060, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Australia. Electronic address: Georgina.Long@sydney.edu.au., Hassel JC; University Hospital Heidelberg, Department of Dermatology and National Center for Cancer (NCT), Im Neuenheimer Feld 460 Heidelberg, 69120, Germany. Electronic address: Jessica.Hassel@med.uni-heidelberg.de., Weide B; University of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany. Electronic address: benjamin.weide@med.uni-tuebingen.de., Haydu LE; University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA. Electronic address: lehaydu@mdanderson.org., Schadendorf D; University Hospital Essen, Department of Dermatology, Essen & German Cancer Consortium, Partner Site Essen, Germany. Electronic address: Dirk.Schadendorf@uk-essen.de., McArthur G; Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: grant.mcarthur@petermac.org., Ott PA; Dana Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA. Electronic address: Patrick_Ott@dfci.harvard.edu., Blank C; Antoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Department of Medical Oncology and Immunology, Plesmanlaan 121 Amsterdam, 1066 CX, the Netherlands. Electronic address: c.blank@nki.nl., Robert C; Gustave Roussy and Paris-Saclay University, 114 rue Edouard Vaillant Villejuif Cedex, 94805, France. Electronic address: caroline.robert@gustaveroussy.fr., Sullivan R; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: RSULLIVAN7@mgh.harvard.edu., Hauschild A; Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Arnold-Heller-Strasse 3, Haus C, Kiel, 24105, Germany. Electronic address: ahauschild@dermatology.uni-kiel.de., Carlino MS; Crown Princess Mary Cancer Centre Westmead, Sydney, NSW, Australia. Electronic address: matteo.carlino@sydney.edu.au., Garbe C; University of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany. Electronic address: claus.garbe@med.uni-tuebingen.de., Davies MA; University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA. Electronic address: MDavies@mdanderson.org., Menzies AM; Melanoma Institute Australia, The University of Sydney, The Poche Centre, 40 Rocklands Road North Sydney NSW 2060, Australia; Royal North Shore Hospital, Reserve Road St Leonards NSW 2065, Australia; Mater Hospital, 25 Rocklands Road, North Sydney NSW 2060, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Electronic address: alexander.menzies@sydney.edu.au.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Feb; Vol. 162, pp. 22-33. Date of Electronic Publication: 2021 Dec 21.

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.

Autor: Knispel S; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Gassenmaier M; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia., Loquai C; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., Johnson DB; Vanderbilt University Medical Center, Nashville, USA., Franklin C; Department of Dermatology and Venereology, Skin Cancer Center at the Center of Integrated Oncology (CIO) Köln Bonn, University Hospital of Cologne, Cologne, Germany., Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany., Hassel JC; Skin Cancer Center, Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany., Weishaupt C; Department of Dermatology, University Hospital of Muenster, Muenster, Germany., Eigentler T; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany., Schilling B; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany., Schummer P; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany., Sirokay J; Department of Dermatology, University Hospital Bonn, Bonn, Germany., Kiecker F; Department of Dermatology, University Hospital Charité Berlin, Berlin, Germany., Owen CN; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Fleischer MI; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., Cann C; Vanderbilt University Medical Center, Nashville, USA., Kähler KC; Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany., Mohr P; Department of Dermatology, Elbe-Klinikum Buxtehude, Buxtehude, Germany., Bluhm L; Department of Dermatology, Elbe-Klinikum Buxtehude, Buxtehude, Germany., Niebel D; Department of Dermatology, University Hospital Bonn, Bonn, Germany., Thoms KM; Department of Dermatology, University Medical Center Goettingen, Göttingen, Germany., Goldinger SM; Department of Dermatology, University Hospital Zürich, Zürich, Switzerland., Reinhardt L; Department of Dermatology, Skin Cancer Center at the National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany., Meier F; Department of Dermatology, Skin Cancer Center at the National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany., Berking C; Department of Dermatology, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen - Metropolitan Region of Nuremberg, Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Reinhard R; Skin Cancer Unit, German Cancer Research Center (DKFZ) and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Mannheim, Germany., Susok L; Department of Dermatology, St. Josef-Hospital Bochum, Bochum, Germany., Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy., Drexler K; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany., Pföhler C; Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany., Tietze J; Department of Dermatology, University Hospital Rostock, Rostock, Germany., Heinzerling L; Department of Dermatology, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen - Metropolitan Region of Nuremberg, Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Livingstone E; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Ugurel S; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia., Stang A; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany., Schadendorf D; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Zimmer L; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Electronic address: lisa.zimmer@uk-essen.de.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 May; Vol. 148, pp. 61-75. Date of Electronic Publication: 2021 Mar 15.

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Autor: Liu D; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Schilling B; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.; Department of Dermatology, University Hospital, Essen, Germany.; German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany., Liu D; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Sucker A; Department of Dermatology, University Hospital, Essen, Germany.; German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany., Livingstone E; Department of Dermatology, University Hospital, Essen, Germany.; German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany., Jerby-Arnon L; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Zimmer L; Department of Dermatology, University Hospital, Essen, Germany.; German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany., Gutzmer R; Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany., Satzger I; Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany., Loquai C; Department of Dermatology, University Medical Center, Mainz, Germany., Grabbe S; Department of Dermatology, University Medical Center, Mainz, Germany., Vokes N; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Margolis CA; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Conway J; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., He MX; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA.; Biophysics Program, Harvard University, Cambridge, MA, USA., Elmarakeby H; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Dietlein F; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Miao D; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Tracy A; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Gogas H; First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Goldinger SM; Department of Dermatology, University Hospital Zürich, Zürich, Switzerland., Utikal J; Department of Dermatology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.; Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Rauschenberg R; Skin Cancer Center at the University Cancer Centre, Department of Dermatology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; National Center for Tumor Diseases, Dresden, Germany.; German Cancer Research Centre, Heidelberg, Germany., von Bubnoff D; Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Krackhardt A; German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany.; Medizinische Klinik III, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany., Weide B; Department of Dermatology, University Medical Center Tübingen, Tübingen, Germany., Haferkamp S; Department of Dermatology, University Hospital Regensburg, Regensburg, Germany., Kiecker F; Department of Dermatology, University Hospital Berlin, Berlin, Germany., Izar B; Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Garraway L; Eli Lilly and Co., Indianapolis, IN, USA., Regev A; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Flaherty K; Massachusetts General Hospital, Boston, MA, USA., Paschen A; Department of Dermatology, University Hospital, Essen, Germany.; German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany., Van Allen EM; Dana-Farber Cancer Institute, Boston, MA, USA. eliezerm_vanallen@dfci.harvard.edu.; Broad Institute of Harvard and MIT, Cambridge, MA, USA. eliezerm_vanallen@dfci.harvard.edu., Schadendorf D; Department of Dermatology, University Hospital, Essen, Germany. dirk.schadendorf@uk-essen.de.; German Cancer Consortium of Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany. dirk.schadendorf@uk-essen.de.

Publikováno v: Nature medicine [Nat Med] 2020 Jul; Vol. 26 (7), pp. 1147.